Connor, Clark & Lunn Investment Management (CC&L)’s CG Oncology CGON Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$313K	Buy	+4,407	New	+$288K	﹤0.01%	1488

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CGON Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in CG Oncology (CGON) in Q2 2026: 4,407 shares worth $313K. The stake represents ﹤0.01% of the portfolio and ranks #1488 among its holdings.

227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 4,407 shares of CG Oncology worth $313K as of Q2 2026.
CG Oncology was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
CG Oncology made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1488 holding.
227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.